Back to top

Analyst Blog

Johnson & Johnson (JNJ - Analyst Report), the first among the large health care companies to report first quarter results, beat expectations yet again. The company’s first-quarter 2014 earnings (excluding special items) were $1.54 per share, well above the Zacks Consensus Estimate of $1.48 per share and 6.9% above the year-ago earnings of $1.44 per share.

Despite the negative impact of currency fluctuation, Johnson & Johnson recorded growth on the back of strong pharma product sales.

Johnson & Johnson’s first quarter sales increased 3.5% year-over-year to $18.1 billion, just above the Zacks Consensus Estimate of $17.9 billion. While operational factors favorably impacted sales by 5.3%, currency fluctuations had a negative impact of 1.8%.

Including one-time items, Johnson & Johnson reported first quarter earnings of $1.64 per share, well above the year-ago earnings of $1.22.

The Quarter in Details

First quarter sales increased 2.2% in the domestic market. Meanwhile, international sales grew 4.5%, consisting of 7.9% operational growth and 3.4% negative currency impact. Only the Pharmaceutical segment recorded growth in the reported quarter with the Medical Devices & Diagnostics segment remaining flat and the Consumer segment declining.

The Medical Devices & Diagnostics segment posted sales of $7.1 billion, unchanged from the year-ago period. Sales, however, declined 2.7% sequentially. While operational factors positively impacted Medical Devices & Diagnostics segment sales by 1.8%, this was offset by negative currency movement.

Sales in the domestic market declined 1.6% year-over year to $3.2 billion; international market sales grew 1.3% year-over-year to $3.9 billion.

Several Medical Devices & Diagnostics markets have been facing challenges in the form of austerity measures, pricing pressure and a slowdown in elective surgeries, which have all contributed to more tempered growth rates.

Pharmaceutical segment sales increased 10.8% year-over-year to $7.5 billion (operational growth of 12.2% and negative currency impact of 1.4%). Sales in the domestic market increased 7.7% to $3.7 billion, whereas international sales increased 14.0% to $3.8 billion.

New products like Zytiga, Invokana, Stelara, Xarelto and Invega Sustenna continued to perform well. Other growth drivers included Prezista, and Velcade. First quarter Zytiga sales were $512 million, up 48.8% year-over-year. Launch in additional countries and the label expansion for use in chemo-naïve patients should continue driving sales.

Meanwhile, sales were hampered to a certain extent by generic competition for products like Aciphex and Concerta.

The Consumer segment recorded revenues of $3.6 billion in the reported quarter, down 3.2% from the first quarter of 2013. Foreign currency movement negatively impacted sales in the segment by 2.6%. Sales in the domestic market declined 2.9% year-over-year to $1.3 billion, reflecting the Oct 2013 divestment of the sanitary protection business.

Meanwhile, the international segment recorded a 3.4% decline in sales with currency having a negative impact of 4.1%. OTC sales increased 3.4% in the U.S. with some key products being re-launched. Johnson & Johnson has been working on ensuring reliable and consistent supply of products.

Ups Earnings Guidance

Following the release of better-than-expected first quarter results, Johnson & Johnson upped its 2014 earnings guidance range by 5 cents to $5.80 - $5.90 per share. The Zacks Consensus Estimate for 2014 is currently $5.83 per share, within the guidance range.

Our Take

Johnson & Johnson’s first quarter results were strong with the company raising its guidance for the year. Johnson & Johnson has been trying to offset the declining sales of some of its important products by bringing in new products through in-licensing deals and acquisitions. The diversity and strength of the company’s underlying businesses should continue to support strong growth in future.

Johnson & Johnson is a Zacks Rank #3 (Hold) stock. Companies that currently look attractive in the healthcare space include Amgen (AMGN - Analyst Report), Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) and Allergan (AGN - Analyst Report). While Amgen and Regeneron are Zacks Rank #1 (Strong Buy) stocks, Allergan is a Zacks Rank #2 (Buy) stock.

Read the Full Research Report on JNJ
Read the Full Research Report on REGN
Read the Full Research Report on AGN
Read the Full Research Report on AMGN

Zacks Investment Research

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%